Ignite Creation Date:
2024-05-06 @ 10:20 AM
Last Modification Date:
2024-10-26 @ 12:28 PM
Study NCT ID:
NCT03226678
Status:
COMPLETED
Last Update Posted:
2023-04-03
First Post:
2017-07-07
Brief Title:
Study to Assess the Safety Tolerability Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia wAIHA or Cold Agglutinin Disease CAD
Sponsor:
Apellis Pharmaceuticals Inc
Organization:
Apellis Pharmaceuticals Inc
Study Overview
Official Title:
An Open Label Prospective Study to Assess the Safety Tolerability Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia wAIHA or Cold Agglutinin Disease CAD
Status:
COMPLETED
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to assess the safety tolerability preliminary efficacy and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia wAIHA or Cold Agglutinin Disease CAD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None